申请人:Société Splicos
公开号:EP2505198A1
公开(公告)日:2012-10-03
The present invention relates to compound (I)
wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a -NHCOphenyl group;
R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a -CONR7R8 group, a -SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a -(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a -(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use as an agent for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53.
Some of said compounds are new and also form part of the invention.
本发明涉及化合物(I),其中R1和R2分别代表氢原子,(C1-C4)烷氧基,氟代(C1-C4)烷氧基,羟基,苄氧基,二(C1-C4)烷基氨基,吡啶基乙烯基,嘧啶基乙烯基,苯乙烯基,或-NHCO苯基;R3、R4和R5分别代表氢原子,(C1-C4)烷基,CONHR6基团,-CONR7R8基团,-SO2NHR6基团,或杂环烷基,可选择地被卤原子取代,-(CH2)nNR7R8基团或羟基(C1-C4)烷基;R6代表氢原子,-(CHR9)m(CH2)nNR7R8基团或(C1-C6)烷基,可选择地被羟基取代;或其药学上可接受的盐之一,用作预防、抑制或治疗患有该疾病的患者的药剂,所述疾病涉及到p53蛋白的失调。其中一些化合物是新的,也是本发明的一部分。